ChemoTech has now completed the delivery of the IQwave™ in the order received earlier this year. An order that was established by the company’s distributor Nobbledrug Healthcare Services (NDHS).
Today ChemoTech and NDHS performed the first training and certification of the D-EECT treatment in Africa. The training took place at one of the larger government referral hospitals in Kenya.
" This is an important mile-stone in our African strategy" says the CEO Mohan Frick, who attended todays training. "Starting a market access in a totally new region, by establishing a government tender is remarkable, and not seen that often. From here, we can start building a strong relation to the hospitals and physicians that works for the government in Kenya and hopefully we will establish more and larger tenders in the future. It’s important to establish good relations with physicians that can partner with us, partners that can train and certify other local physicians in the region."
För mer information vänligen kontakta:
Mohan Frick, CEO
+46 (0)10-218 93 00
Certified Adviser: Västra Hamnen Corporate Finance AB, Tel: +46 40 200 250,
Scandinavian ChemoTech AB (publ)
ChemoTech is a life science company that possesses a great medical expertise and technical knowledge. Our latest launch of IQWave™ is an innovation within electroporation, that is adapted for the treatment of different types of tumors. ChemoTech strives to contribute to a more accessible cancer care. ChemoTech’s shares (CMOTEC B) are listed on Nasdaq First North in Stockholm and Västra Hamnen Corporate Finance AB is the company’s Certified Adviser. The company is headquartered in Malmö, in the midst of the medical technology expansionary Öresund region.
Se fullständiga pressmeddelande och andra nyheter från detta bolag hos Cision News